AIM:EVG

Stock Analysis Report

Executive Summary

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases.

Rewards

Earnings have grown 1.1% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of -8.9% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Evgen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.3%

EVG

2.0%

GB Biotechs

-1.1%

GB Market


1 Year Return

-59.4%

EVG

9.1%

GB Biotechs

11.8%

GB Market

Return vs Industry: EVG underperformed the UK Biotechs industry which returned 7.8% over the past year.

Return vs Market: EVG underperformed the UK Market which returned 12.7% over the past year.


Shareholder returns

EVGIndustryMarket
7 Day-2.3%2.0%-1.1%
30 Day-8.5%0.5%-0.8%
90 Day-55.6%13.8%5.2%
1 Year-59.4%-59.4%10.0%9.1%17.7%11.8%
3 Year-69.0%-69.0%9.3%7.6%21.3%5.8%
5 Yearn/a47.9%44.4%40.0%7.7%

Price Volatility Vs. Market

How volatile is Evgen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?

1.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EVG is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVG is good value based on its PB Ratio (1.5x) compared to the GB Biotechs industry average (1.8x).


Next Steps

Future Growth

How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if EVG's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if EVG's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evgen Pharma performed over the past 5 years?

1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVG is currently unprofitable.

Growing Profit Margin: EVG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVG is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare EVG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: EVG has a negative Return on Equity (-46.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Evgen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVG's short term assets (£5.5M) exceed its short term liabilities (£353.0K).

Long Term Liabilities: EVG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVG is debt free.

Reducing Debt: EVG currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: EVG has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if EVG's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVG has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 13.6% each year.


Next Steps

Dividend

What is Evgen Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%5.0%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EVG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EVG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Evgen Pharma's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Steve Franklin 0

0yrs

Tenure

UK£228,300

Compensation

Dr. Stephen J. Franklin, also known as Steve, serves Chief Executive Officer of Evgen Pharma Plc. He has been an Executive Director at Evgen Pharma plc since October 2, 2014. He has over 20 years’ commerci ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD296.86K) is about average for companies of similar size in the UK market ($USD326.78K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.4yrs

Average Tenure

Experienced Management: EVG's management team is considered experienced (2.4 years average tenure).


Board Age and Tenure

3.1yrs

Average Tenure

61.5yo

Average Age

Experienced Board: EVG's board of directors are considered experienced (3.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Management Team

  • Richard Moulson (57yo)

    CFO & Executive Director

    • Tenure: 3yrs
    • Compensation: UK£93.68k
  • Steve Franklin

    CEO & Executive Director

    • Compensation: UK£228.30k
  • Liz Jenkins

    Regulatory Consultant

    • Tom Morris

      Consultant & Medical Advisor of Oncology

      • Tenure: 2.8yrs
    • Albena Dinkova-Kostova

      Independent Scientific Advisor

      • Tenure: 2yrs
    • Giovanni Mann

      Independent Scientific Advisor

      • Tenure: 2yrs

    Board Members

    • Richard Moulson (57yo)

      CFO & Executive Director

      • Tenure: 3yrs
      • Compensation: UK£93.68k
    • Sue Foden (66yo)

      Senior Independent Director

      • Compensation: UK£26.50k
    • Barry Clare (66yo)

      Non-Executive Chairman

      • Tenure: 3.1yrs
      • Compensation: UK£35.00k
    • Steve Franklin

      CEO & Executive Director

      • Compensation: UK£228.30k
    • Alan Barge

      Non-Executive Director

      • Tenure: 4.3yrs
      • Compensation: UK£24.30k
    • Susan Clement-Davies (56yo)

      Non-Executive Director

      • Tenure: 1.2yrs
      • Compensation: UK£9.38k

    Company Information

    Evgen Pharma plc's company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Evgen Pharma plc
    • Ticker: EVG
    • Exchange: AIM
    • Founded: 2007
    • Industry: Biotechnology
    • Sector: Pharmaceuticals & Biotech
    • Market Cap: UK£8.622m
    • Shares outstanding: 132.65m
    • Website: https://www.evgen.com

    Number of Employees


    Location

    • Evgen Pharma plc
    • The Colony
    • Altrincham Road
    • Wilmslow
    • Cheshire
    • SK9 4LY
    • United Kingdom

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    EVGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2015
    8EVDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2015

    Biography

    Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/23 22:19
    End of Day Share Price2020/01/23 00:00
    Earnings2019/09/30
    Annual Earnings2019/03/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.